Nine More States Offer Medicaid Coverage for Breast and Cervical Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

WASHINGTON-Health and Human Services Secretary Tommy Thompson has given nine more states the go-ahead to extend Medicaid benefits to uninsured women diagnosed with cancer under the federal Breast and Cervical Cancer Prevention and Treatment Act of 2000.

WASHINGTON—Health and Human Services Secretary Tommy Thompson has given nine more states the go-ahead to extend Medicaid benefits to uninsured women diagnosed with cancer under the federal Breast and Cervical Cancer Prevention and Treatment Act of 2000. 

Alabama, Georgia, Iowa, Mississippi, Missouri, North Dakota, South Carolina, Virginia, and Washington join 19 previously approved states.

Articles in this issue
High-Dose IL-2 Is Standard in Advanced Renal Cell Cancer
RIT Safe, Effective in Elderly and Poor-Prognosis Patients
FDA Approves Xeloda/Taxotere Combination for Advanced Breast Cancer
ODAC Recommends Approval of Radiolabeled Zevalin
Proteomics Moves From the Laboratory to Clinical Research
Radiotherapy Not Needed in Older Lumpectomy Patients With Early Cancer
Raltitrexed + Oxaliplatin for Advanced Colorectal Cancer
Mental Fatigue Worries Chemotherapy Patients
Patients Urged to Work With Professionals Against Fatigue
NCI Director Resigns to Head New Scientific Institute
Combined PET/CT Aids in Head and Neck Cancer Management
MRI Method Predicts Early Response
New Cellular Target Shows Promise in Cancer Treatment
ACR Protests Proposed Diagnostic Mammography Reimbursement Rates
High-Volume Hospitals Better for Some Cancer Surgeries

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA Data in Gynecologic Cancer RT Population May Be Hypothesis-Generating
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
ctDNA Clearance Confers Responses to Radiation in Gynecologic Malignancies
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
Assessing ctDNA as a Predictor of RT Responses in Gynecologic Cancers
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Overcoming Barriers to Trial Enrollment and Gaps in Gynecologic Cancer Care
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Advancing Prevention and Genetic Testing Methods in Uterine Cancer
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Raising Awareness to Address the Rising Incidence of Gynecologic Cancers
Fertility Preservation Rates May Increase With Uterine Transposition in Pelvic Cancers
Fertility Preservation Rates May Increase With Uterine Transposition in Pelvic Cancers
Uterine Transposition Aims to Preserve Fertility During Radiation
Uterine Transposition Aims to Preserve Fertility During Radiation
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
ADCs May “Change the World” in Gynecologic Cancer Management
Related Content
The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer

Roman Fabbricatore
April 2nd 2025
Article

The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Increased incidence and mortality rates for cervical cancer among rural women in the US may result from barriers to access to care.

Women in Rural Regions Experience Greater Cervical Cancer Incidence/Mortality

Roman Fabbricatore
March 25th 2025
Article

Increased incidence and mortality rates for cervical cancer among rural women in the US may result from barriers to access to care.

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Patients who had recurrence in the radiation field experienced similar responses vs those with recurrence outside the radiation field.

Immunotherapy Sustains Responses in Radiated Endometrial/Cervical Cancer

Roman Fabbricatore
March 18th 2025
Article

Patients who had recurrence in the radiation field experienced similar responses vs those with recurrence outside the radiation field.

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.

Uterine Cancer Survival Rates Have Improved Despite Higher Mortality Risks

Russ Conroy
March 18th 2025
Article

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.